Results 281 to 290 of about 6,463,095 (311)

A Hemorrhagic Clival Chordoma with a Long Progression-Free Survival

World Neurosurgery, 2017
Chordomas and ecchordosis physaliphora may on rare occasions present with intracranial hemorrhage. Their distinction usually relies on the results of the Ki-67 proliferative index, with a result lower than 1% favoring ecchordosis physaliphora. Intracranial hemorrhagic chordomas have been linked to unfavorable prognosis, due to acute neurologic ...
Marcelo D, Vilela, Hugo A S, Pedrosa, Marco Antonio, Dias Filho   +2 more
openaire   +2 more sources

Evaluating and Adjusting for Premature Censoring of Progression-Free Survival

Journal of Biopharmaceutical Statistics, 2013
The intent-to-treat principle, grouping subjects as they were randomized and following all subjects to the endpoint or the end of study, allows valid statistical comparisons. Progression-free survival (PFS) has been used as a decision-making endpoint in oncology.
Mark, Rothmann, Kallappa, Koti, Kyung Yul, Lee, Hong Laura, Lu, Yuan Li, Shen, Jenny J, Zhang, Mei, Jin, Haojin, Zhou   +7 more
openaire   +2 more sources

Evaluating Post-Progression Survival in the Context of Progression-Free Survival Benefits: A Revisit of the CodeBreaK200 Design

Therapeutic Innovation & Regulatory Science
Overall survival (OS) remains the gold-standard endpoint in oncology trials, while progression-free survival (PFS) is a widely used surrogate endpoint that captures tumor progression earlier. However, an increase in PFS has not necessarily led to an improvement in OS (Reck M, 2009). The recent CodeBreaK 200 trial, a randomized, open-label Phase 3 study
Zhoujingpeng, Wei, Yuanyuan, Han, Luoying, Yang, Pourab, Roy, Chunsheng, He, Liangang, Liu, Shu-Pang, Huang, Hsin-Ju, Hsieh   +7 more
openaire   +2 more sources

Classification of progression free survival with nasopharyngeal carcinoma tumors

SPIE Proceedings, 2016
Nasopharyngeal carcinoma (NPC) is an abnormal growth of tissue which arises from the back of the nose. At the time of diagnosis, detection of tumor features with prognostic significance, including patient demographics, imaging characteristics and molecular characteristics, can enable the treating clinician to select a treatment that is optimized for ...
Hamidreza Farhidzadeh, Joo Y. Kim, Jacob G. Scott, Dmitry B. Goldgof, Lawrence O. Hall, Louis B. Harrison   +5 more
openaire   +1 more source

Progression-free survival as a surrogate for overall survival in advanced cancer.

Journal of Clinical Oncology, 2015
e17765 Background: Progression-free survival (PFS) is sometimes being used instead of overall survival (OS) as a primary end-point in clinical trials of advanced cancer patients (ACP).
Eric Gillies, Veera Holdai, David Eric Cowall   +2 more
openaire   +1 more source

Progression-free survival: it is time for a new name

The Lancet Oncology, 2022
Bishal, Gyawali, Elizabeth, Eisenhauer, Michelle, Tregear, Christopher M, Booth   +3 more
openaire   +2 more sources

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of Oncology, 2020
Solange Peters, D R Camidge, S M Gadgeel
exaly  

Progression Free Survival

2010
openaire   +1 more source

Valid Analysis of Brain-Specific Progression-Free Survival

JAMA Oncology
Stephanie, Armbruster, Ethan B, Ludmir, Lee-Jen, Wei   +2 more
openaire   +4 more sources

Progression-Free Survival

2011
openaire   +1 more source